Engimmune Therapeutics Announces the Appointment of Dr Annalisa D’Andrea to its Board of Directors

Leading industry expert with more than 25 years of experience in translation research in immunology BASEL, Switzerland, May 23, 2023 /PRNewswire/ — Engimmune Therapeutics AG (“Engimmune”), a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, is pleased to…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.